VDRL Test: Syphilis Screening Blood Test Explained

Key takeaways

• The VDRL test is a screening test, not a diagnosis of syphilis.
• A reactive VDRL test needs a treponemal confirmatory test such as TPHA, TPPA or FTA-ABS.
• A non-reactive VDRL test does not exclude very early syphilis, and may be non-reactive in some late-stage infection.
• Quantitative VDRL titres are used to follow response to treatment, comparing results from the same laboratory and same method.
• Interpretation belongs to the doctor who requested the test, in the context of symptoms, exposure history and stage.

At a glance

Also known as

• VDRL test, VDRL slide test
• Syphilis screening test; "syphilis blood test"
• STD/STI panel component
• Non-treponemal test (the related RPR test is often used interchangeably in Indian labs and reported as "RPR/VDRL")
• CSF-VDRL, when performed on cerebrospinal fluid

What the VDRL test is

The VDRL test mixes serum with a cardiolipin-based antigen. If reagin antibodies are present, visible clumping (flocculation) occurs and the result is reported as reactive. The laboratory then dilutes the serum step by step to find the highest dilution that still reacts, this is the titre.

Because the antigen is not a component of Treponema pallidum, the VDRL test is called non-treponemal. That design makes the VDRL test useful for screening and for tracking treatment response, but it also means other conditions can produce reactive results.

Why the VDRL test is done

• Screening: as part of antenatal care, STI panels, blood and organ donor screening, and pre-operative or pre-employment panels in some settings.
• Supporting a diagnosis: in a person with genital ulcer, rash involving palms and soles, mucosal lesions or unexplained lymphadenopathy.
• Monitoring treatment: a fall in quantitative titre after penicillin therapy supports an adequate response.
• Detecting reinfection: a rise in titre after previously low or non-reactive results raises that possibility.
• Assessing possible neurosyphilis: CSF-VDRL is used alongside CSF cell count, protein and clinical findings.

Who should get this test

• All pregnant women, as recommended in Indian antenatal care; repeat testing later in pregnancy may be advised where risk is higher.
• Anyone with a genital, anal or oral ulcer, or an unexplained widespread rash including palms and soles.
• People diagnosed with another sexually transmitted infection, including HIV, gonorrhoea, chlamydia or hepatitis B.
• Sexual partners and contacts of someone diagnosed with syphilis.
• People with new or multiple partners, men who have sex with men, sex workers, and people who ask for an STI check.
• Newborns of mothers with reactive syphilis serology, evaluated with paired maternal and infant testing.
• People with unexplained neurological, visual or hearing symptoms where syphilis is a consideration.
• People on HIV pre-exposure prophylaxis, as part of periodic review.

Screening decisions should be made with your doctor. The VDRL test is not a routine test for everyone.

What the VDRL test cannot detect or exclude

• It cannot confirm syphilis. A reactive VDRL test alone is not a diagnosis. Confirmation with a treponemal test is required.
• It cannot exclude very early syphilis. In the window period soon after exposure, and in some people with a primary chancre, the VDRL test may still be non-reactive. Repeat testing after an interval advised by your doctor may be needed.
• It cannot reliably exclude late or latent syphilis. Non-treponemal titres fall with time and may become non-reactive despite untreated infection; treponemal tests are more useful here.
• It cannot exclude neurosyphilis. A non-reactive CSF-VDRL does not exclude central nervous system involvement; CSF-VDRL is specific but insensitive.
• It cannot stage the infection or tell primary from secondary from latent disease on its own.
• It cannot distinguish syphilis from other treponemal infections such as yaws or pinta.
• It cannot tell active infection from past treated infection without previous titres for comparison.
• It does not test for other STIs. HIV, hepatitis B and C, gonorrhoea and chlamydia need their own tests.

A result that is "not identified" describes what the test detected, not what is absent. If symptoms continue or exposure risk persists despite a non-reactive VDRL test, go back to your doctor rather than assuming you are in the clear.

Related but different examinations

Which test comes first depends on the clinical problem. In a person with a fresh genital ulcer, direct lesion testing or a treponemal test may add most; in antenatal screening, a non-treponemal or treponemal screen followed by the complementary test is usual; in follow-up after treatment, a quantitative VDRL or RPR is the relevant test. No single test is superior for all situations. Laboratory algorithms differ between facilities.

How to prepare

• Fasting: not required for the blood VDRL test. If the same visit includes glucose or lipid tests, follow the instructions given for those.
• Medicines: tell the laboratory and your doctor what you take, including anticoagulants and recent antibiotics. Do not stop or change any prescribed medicine yourself, speak to the prescriber.
• Recent events to mention: pregnancy, recent vaccination, recent viral illness, autoimmune disease, injecting drug use, malaria, tuberculosis treatment, or previous syphilis treatment with known titres.
• Previous reports: bring old VDRL or RPR reports. Comparison with earlier titres changes interpretation substantially.
• Alcohol: heavy recent alcohol intake can affect some serological tests; mention it.

Sample handling, reporting format, titre reporting practice and appointment rules are operational matters that differ between laboratories. Your own unit's written instructions take precedence over any general guidance here.

If you are pregnant

The blood test involves a routine venous sample and is used widely in antenatal care. Testing early in pregnancy matters because treated maternal syphilis substantially reduces the risk of congenital syphilis. Pregnancy itself can occasionally cause a false-reactive non-treponemal test, so confirmation is part of the pathway.

Children and newborns

Newborn evaluation uses paired maternal and infant quantitative titres, examination, and often further tests. Maternal antibodies cross the placenta, so a reactive newborn result does not by itself mean the baby is infected. Paediatric blood sampling should be done by staff experienced with infants.

People with bleeding disorders or on anticoagulants

Tell the phlebotomist. Longer pressure over the puncture site is usually needed and bruising is more likely.

If a lumbar puncture is planned for CSF-VDRL

A lumbar puncture is a different procedure from a blood draw, with its own consent, positioning, and risks such as headache, backache and, uncommonly, bleeding or infection. It is avoided or done with extra caution where there is raised intracranial pressure, a bleeding tendency, anticoagulant therapy or local skin infection. Your neurologist or physician will explain the specific plan.

What happens during the test

• Blood collection: the skin over a vein, usually in the forearm or elbow crease, is cleaned; a needle is inserted and a small tube of blood is filled. The draw itself typically takes 2-5 minutes.
• Total visit: commonly 15-30 minutes including registration and waiting, longer at busy times.
• After the draw: pressure is applied over the site. Most people resume normal activity immediately.
• Laboratory step: serum is mixed with the VDRL antigen and read for flocculation. Reactive samples are serially diluted for a titre.
• CSF sampling: when needed, a lumbar puncture is performed by a doctor, usually taking 20-40 minutes including preparation, with a period of rest afterwards as advised by the unit.

Understanding your report

The VDRL report is usually qualitative (reactive or non-reactive) with a titre when reactive.

• Non-reactive: no reagin antibodies detected at the tested dilution. This does not exclude very early infection or some late latent infection.
• Weakly reactive or borderline: may reflect early infection, a biological false-reactive result, or a technical issue. Repeat and confirmatory testing is usual.
• Reactive with titre: antibodies detected. Higher titres are more often seen in secondary syphilis, but a titre alone does not establish stage or activity.
• Titre trends: a sustained fall of two dilution steps (for example 1:32 to 1:8) after treatment is generally taken as a favourable serological response. A fourfold rise suggests reinfection, relapse or treatment failure. Compare only results from the same test type and, ideally, the same laboratory.
• Serofast state: some treated people keep a low stable titre long term without active infection.

The VDRL test does not diagnose syphilis on its own, and no result should be interpreted from the report alone. The doctor who requested the test interprets it with your history, examination, stage, prior titres and confirmatory test results. Results vary depending on individual clinical circumstances.

When results can be misleading

Falsely reactive (false positive)

• Pregnancy.
• Autoimmune conditions, particularly systemic lupus erythematosus and antiphospholipid syndrome.
• Recent viral infections, recent immunisation, and some acute febrile illnesses.
• Malaria, tuberculosis, leprosy, and some rickettsial and endemic infections relevant in India.
• Injecting drug use, chronic liver disease, lymphoma and other malignancies.
• Older age and multiple prior transfusions.
• Other treponemal infections such as yaws, which produce genuinely reactive serology but are not venereal syphilis.

Falsely non-reactive (false negative)

• Window period: too early after exposure for antibodies to appear.
• Prozone phenomenon: very high antibody levels, typically in secondary syphilis or pregnancy, can block visible flocculation in undiluted serum. Laboratories manage this by testing diluted serum; if secondary syphilis is clinically likely, mention it on the request.
• Late latent or tertiary disease: titres fall over years and may become non-reactive.
• Immunosuppression and unusual antibody responses.
• Sample handling, delay or technical error.

Other sources of confusion

• Comparing a VDRL titre with an RPR titre from a different laboratory can look like a change when none has occurred.
• Blood contamination of cerebrospinal fluid during lumbar puncture can make CSF-VDRL hard to interpret.
• A previously treated infection can leave a persistently reactive treponemal test, which is not evidence of new infection.

Risks and safety

Venous blood sampling

Generally low risk. Possible effects include brief pain, bruising, a small haematoma, light-headedness or fainting, and rarely local infection or nerve irritation. Bruising is more likely on anticoagulants or with a bleeding disorder.

Lumbar puncture for CSF-VDRL

A more involved procedure with a different risk profile: post-procedure headache is the commonest problem, along with backache and transient nerve-root pain. Bleeding, infection and, in specific situations, neurological complications are uncommon but serious. The procedure is performed only when clinically justified, after assessment and consent.

Emotional and social considerations

Syphilis testing carries stigma for many people. Test results are confidential health information handled in line with the Digital Personal Data Protection Act, 2023 and professional confidentiality obligations. Partner notification is handled sensitively and with your involvement.

Special situations

Pregnancy

Antenatal syphilis screening is standard practice in India and is part of national maternal health programmes. Treatment during pregnancy, with penicillin as the agent of choice, reduces the risk of congenital syphilis; alternatives are less well established for protecting the fetus, so penicillin allergy needs specialist input. Pregnancy can also cause a false-reactive non-treponemal result, which is why confirmation is done. Repeat testing later in pregnancy or at delivery may be advised depending on risk.

Newborns and children

Diagnosis in a newborn is not made on the baby's VDRL result alone. Evaluation combines maternal treatment history, paired titres, examination, and further investigations chosen by the paediatrician.

People living with HIV

Syphilis and HIV frequently occur together. Serological responses can be atypical, with unusually high or slow-falling titres, and neurological involvement is a greater concern. Testing intervals and follow-up are usually more frequent.

Older adults

Low-titre reactive non-treponemal results become more common with age and other illnesses, so confirmatory testing is particularly important before concluding anything.

People with autoimmune disease

Lupus and antiphospholipid syndrome are well-recognised causes of false-reactive VDRL results. Tell your doctor if you have either diagnosis.

Blood and organ donors

Syphilis screening is a mandatory part of donor testing in India. A reactive donor screen requires confirmatory evaluation and clinical follow-up rather than assumptions.

The VDRL test in the Indian context

• Availability: the VDRL and RPR tests are among the most widely available serological tests in India, offered at government primary health centres, district hospitals, ICTC/designated STI clinics and private laboratories.
• Programme context: syphilis screening in pregnancy is embedded in India's reproductive and child health services, and free testing is available at many public facilities.
• Terminology: patients commonly ask for a "VDRL test", "syphilis test" or "STD test"; many Indian reports print "VDRL/RPR" together. Check which method was used before comparing titres.
• Co-existing conditions that matter locally: malaria, tuberculosis, leprosy, hepatitis B and C, and HIV are all relevant either as causes of false-reactive results or as co-infections worth testing for.
• Confidentiality: personal health data, including STI results, is protected under the Digital Personal Data Protection Act, 2023, and by professional conduct obligations under the National Medical Commission framework.
• Advertising law: claims of guaranteed cure for sexually transmitted infections are prohibited under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Syphilis is treatable with prescribed antibiotics under medical supervision; avoid unregulated clinics promising quick fixes.

Cost and insurance in India

A standalone VDRL or RPR test is among the lower-cost serological tests in India and is often free at government facilities, especially for antenatal screening. Private charges differ widely between cities and laboratories. Costs shown on any price list are indicative only and change; confirm the current charge with the facility before testing.

What influences cost

• Whether the test is qualitative only, or quantitative with a titre.
• Whether a confirmatory treponemal test (TPHA/TPPA or immunoassay) is added.
• Bundling within an STI, antenatal or pre-operative panel.
• Government versus private facility, city tier, and laboratory accreditation status.
• Home sample collection, urgent processing, or after-hours service.
• CSF testing, which adds the cost of a lumbar puncture and day-care use.

Insurance

Outpatient diagnostic tests are often not covered by standard Indian indemnity health insurance unless linked to an admission or covered by an OPD rider or corporate plan. Coverage for tests related to sexually transmitted infections varies by policy wording. Check with your insurer or the hospital's insurance desk before assuming reimbursement.

Myths and facts

Frequently asked questions

How long does the VDRL test take?

The blood draw itself usually takes 2-5 minutes, with a typical visit of 15-30 minutes including registration. Laboratory processing time and reporting differ between facilities, so ask the collection centre when your report will be issued and how it will be shared with you.

Do I need to fast before a VDRL test?

No. Fasting is not required for the VDRL test and you can eat and drink normally. If other tests such as fasting glucose or lipids are booked at the same visit, follow the instructions for those. Tell the staff about medicines, pregnancy and recent illnesses.

What is the difference between VDRL and TPHA?

The VDRL test detects non-specific reagin antibodies and gives a titre useful for monitoring treatment. TPHA detects antibodies specific to Treponema pallidum and is used for confirmation, but usually stays reactive for life, so TPHA cannot show whether treatment has worked.

Is VDRL the same as RPR?

Both are non-treponemal tests answering the same clinical question, but they use different antigen carriers and reading methods. Their titres are not interchangeable. If you are being followed after treatment, ask for the same test in the same laboratory each time to allow meaningful comparison.

How soon after exposure will a VDRL test become reactive?

Antibodies take time to develop, so testing very soon after a possible exposure can be non-reactive even if infection has occurred. Your doctor will advise when to repeat the test based on the exposure date, symptoms and risk. Direct lesion testing may be considered if an ulcer is present.

Can a VDRL test be reactive without syphilis?

Yes. Pregnancy, lupus and antiphospholipid syndrome, recent viral illness or vaccination, malaria, tuberculosis, leprosy, chronic liver disease, some cancers and older age can all produce false-reactive results. This is why a specific treponemal confirmatory test is always needed before any diagnosis is made.

What happens if my VDRL test is reactive?

Your doctor will arrange a confirmatory treponemal test, take a detailed history, examine you, and usually offer HIV and other STI testing. If syphilis is confirmed, treatment with prescribed antibiotics, staging assessment, partner notification and scheduled follow-up titres are planned together with you.

Can the VDRL test diagnose neurosyphilis?

CSF-VDRL supports the diagnosis when reactive, but a non-reactive CSF-VDRL does not exclude neurosyphilis because the test is insensitive in spinal fluid. Diagnosis combines CSF cell count and protein, blood serology, neurological findings and sometimes other CSF tests chosen by the specialist.

Will my VDRL result be kept confidential?

Health records, including STI test results, are confidential and handled under the Digital Personal Data Protection Act, 2023 and professional confidentiality duties. Results are shared with you and your treating doctor. Partner notification, when relevant, is discussed with you rather than done without your knowledge.

Sources

• World Health Organization, guidelines on the management of syphilis and on syphilis screening and treatment for pregnant women.
• Centers for Disease Control and Prevention, Sexually Transmitted Infections Treatment Guidelines, syphilis and congenital syphilis sections.
• National AIDS Control Organisation (NACO), Ministry of Health and Family Welfare, India, national guidelines on management of sexually transmitted infections and reproductive tract infections.
• Indian Council of Medical Research, standard treatment and laboratory diagnostic guidance for sexually transmitted infections.
• Digital Personal Data Protection Act, 2023; Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Government of India.